Enterome is a clinical-stage company pioneering the development of novel pharmaceuticals based on its leading knowledge of the interaction between the immune system and the gut microbiome. The Company was established in 2012 in Paris to develop the discoveries made by INRA on gut metagenomics. The Company is backed by leading venture capital investors (Seventure Partners, Lundbeckfonden Ventures, Health for Life Capital, Omnes Capital and Principia) and strategic investors (BMS, Nestlé Health Science, Shire and INRA Transfert).
Enterome is advancing a pipeline of small molecules and peptide candidates to treat microbiome-associated diseases with a focus on auto-immune disease and cancer: these include EB8018, a selective clinical-stage FimH blocker in Crohns disease and EO2401, an innovative “onco-mimic” therapeutic vaccine in Glioblastoma.
The Company’s strategic drug discovery is driven by its proprietary metagenomics platform enabling the identification of new targets and therapeutic candidates derived from the microbiome. Enterome’s partners include Johnson & Johnson Innovation/Janssen Biotech, Takeda and Bristol-Myers Squibb.